358 related articles for article (PubMed ID: 18224704)
1. A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking.
Karkola S; Lilienkampf A; Wähälä K
ChemMedChem; 2008 Mar; 3(3):461-72. PubMed ID: 18224704
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
Karkola S; Alho-Richmond S; Wahala K
Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
[TBL] [Abstract][Full Text] [Related]
4. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.
Laplante Y; Cadot C; Fournier MA; Poirier D
Bioorg Med Chem; 2008 Feb; 16(4):1849-60. PubMed ID: 18035543
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
6. Docking-based 3D-QSAR study for 11beta-HSD1 inhibitors.
Lee JH; Kang NS; Yoo SE
Bioorg Med Chem Lett; 2008 Apr; 18(7):2479-90. PubMed ID: 18314331
[TBL] [Abstract][Full Text] [Related]
7. New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity.
Bey E; Marchais-Oberwinkler S; Negri M; Kruchten P; Oster A; Klein T; Spadaro A; Werth R; Frotscher M; Birk B; Hartmann RW
J Med Chem; 2009 Nov; 52(21):6724-43. PubMed ID: 19831396
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Bey E; Marchais-Oberwinkler S; Kruchten P; Frotscher M; Werth R; Oster A; Algül O; Neugebauer A; Hartmann RW
Bioorg Med Chem; 2008 Jun; 16(12):6423-35. PubMed ID: 18514529
[TBL] [Abstract][Full Text] [Related]
9. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer.
Purohit A; Tutill HJ; Day JM; Chander SK; Lawrence HR; Allan GM; Fischer DS; Vicker N; Newman SP; Potter BV; Reed MJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):199-203. PubMed ID: 16414180
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1).
Bey E; Marchais-Oberwinkler S; Werth R; Negri M; Al-Soud YA; Kruchten P; Oster A; Frotscher M; Birk B; Hartmann RW
J Med Chem; 2008 Nov; 51(21):6725-39. PubMed ID: 18855374
[TBL] [Abstract][Full Text] [Related]
11. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
[TBL] [Abstract][Full Text] [Related]
12. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
[TBL] [Abstract][Full Text] [Related]
13. Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents.
Kruchten P; Werth R; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):154-7. PubMed ID: 18984028
[TBL] [Abstract][Full Text] [Related]
14. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
15. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.
Schuster D; Nashev LG; Kirchmair J; Laggner C; Wolber G; Langer T; Odermatt A
J Med Chem; 2008 Jul; 51(14):4188-99. PubMed ID: 18533708
[TBL] [Abstract][Full Text] [Related]
16. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
17. Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Vicker N; Lawrence HR; Allan GM; Bubert C; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
ChemMedChem; 2006 Apr; 1(4):464-81. PubMed ID: 16892382
[TBL] [Abstract][Full Text] [Related]
18. Probing the origins of 17β-hydroxysteroid dehydrogenase type 1 inhibitory activity via QSAR and molecular docking.
Srungboonmee K; Songtawee N; Monnor T; Prachayasittikul V; Nantasenamat C
Eur J Med Chem; 2015; 96():231-7. PubMed ID: 25884113
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity study in the class of 6-(3'-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors.
Marchais-Oberwinkler S; Frotscher M; Ziegler E; Werth R; Kruchten P; Messinger J; Thole H; Hartmann RW
Mol Cell Endocrinol; 2009 Mar; 301(1-2):205-11. PubMed ID: 18950679
[TBL] [Abstract][Full Text] [Related]
20. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Laplante Y; Rancourt C; Poirier D
Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
